Literature DB >> 17569630

Matriptase-dependent cell surface proteolysis in epithelial development and pathogenesis.

Thomas H Bugge1, Karin List, Roman Szabo.   

Abstract

Matriptase is an epithelial type II transmembrane serine protease with a complex modular structure and sophisticated activation mechanism. Reduced matriptase activity in mice or humans is associated with incomplete terminal differentiation of epidermis, epidermal appendages, oral epithelium, and, likely, other epithelial structures. Preliminary evidence indicates that matriptase is part of a serine protease zymogen activation cascade that regulates epithelial cell proliferation and fate. Matriptase activity must be tightly controlled in epithelial tissues by transcriptional and posttranslational mechanisms, as matriptase dysregulation can cause embryonic demise as well as malignant transformation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17569630     DOI: 10.2741/2448

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  20 in total

1.  Differential tumorigenic potential and matriptase activation between PDGF B versus PDGF D in prostate cancer.

Authors:  Abdo J Najy; Joshua J Won; Lisa S Movilla; Hyeong-Reh C Kim
Journal:  Mol Cancer Res       Date:  2012-06-11       Impact factor: 5.852

Review 2.  Type II transmembrane serine proteases.

Authors:  Thomas H Bugge; Toni M Antalis; Qingyu Wu
Journal:  J Biol Chem       Date:  2009-06-01       Impact factor: 5.157

3.  Requirement of the activity of hepatocyte growth factor activator inhibitor type 1 for the extracellular appearance of a transmembrane serine protease matriptase in monkey kidney COS-1 cells.

Authors:  Yuka Miyake; Satoshi Tsuzuki; Makoto Yasumoto; Tohru Fushiki; Kuniyo Inouye
Journal:  Cytotechnology       Date:  2009-08-05       Impact factor: 2.058

4.  Polarized epithelial cells secrete matriptase as a consequence of zymogen activation and HAI-1-mediated inhibition.

Authors:  Jehng-Kang Wang; Ming-Shyue Lee; I-Chu Tseng; Feng-Pai Chou; Ya-Wen Chen; Amy Fulton; Herng-Sheng Lee; Cheng-Jueng Chen; Michael D Johnson; Chen-Yong Lin
Journal:  Am J Physiol Cell Physiol       Date:  2009-06-17       Impact factor: 4.249

5.  Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.

Authors:  Manisha Tripathi; Alka A Potdar; Hironobu Yamashita; Brandy Weidow; Peter T Cummings; Daniel Kirchhofer; Vito Quaranta
Journal:  Prostate       Date:  2011-02-01       Impact factor: 4.104

6.  Roles of CUB and LDL receptor class A domain repeats of a transmembrane serine protease matriptase in its zymogen activation.

Authors:  Kuniyo Inouye; Marie Tomoishi; Makoto Yasumoto; Yuka Miyake; Kenji Kojima; Satoshi Tsuzuki; Tohru Fushiki
Journal:  J Biochem       Date:  2012-10-03       Impact factor: 3.387

7.  Identification of the matriptase second CUB domain as the secondary site for interaction with hepatocyte growth factor activator inhibitor type-1.

Authors:  Kuniyo Inouye; Satoshi Tsuzuki; Makoto Yasumoto; Kenji Kojima; Seiya Mochida; Tohru Fushiki
Journal:  J Biol Chem       Date:  2010-08-03       Impact factor: 5.157

Review 8.  Advances in salivary gland gene therapy - oral and systemic implications.

Authors:  Bruce J Baum; Ilias Alevizos; John A Chiorini; Ana P Cotrim; Changyu Zheng
Journal:  Expert Opin Biol Ther       Date:  2015-07-06       Impact factor: 4.388

9.  Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine.

Authors:  Marguerite S Buzza; Sarah Netzel-Arnett; Terez Shea-Donohue; Aiping Zhao; Chen-Yong Lin; Karin List; Roman Szabo; Alessio Fasano; Thomas H Bugge; Toni M Antalis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-08       Impact factor: 11.205

10.  Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.

Authors:  Feng-Pai Chou; Ya-Wen Chen; Xianfeng F Zhao; Zijun Y Xu-Monette; Ken H Young; Ronald B Gartenhaus; Jehng-Kang Wang; Hiroaki Kataoka; Annie H Zuo; Robert J Barndt; Michael Johnson; Chen-Yong Lin
Journal:  Am J Pathol       Date:  2013-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.